Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • Communities & Collections
  • Research Outputs
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Medicine
  3. Faculty of Medicine
  4. Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis
 
  • Details
Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis
File(s)
Submission_JTH final.pdf (604.02 KB)
Accepted version
Author(s)
Maino, A
Siegerink, B
Lotta, LA
Crawley, JTB
Le Cessie, S
more
Type
Journal Article
Abstract
Background
Low ADAMTS-13 levels have been repeatedly associated with an increased risk of ischemic stroke, but results concerning the risk of myocardial infarction are inconclusive.

Objectives
To perform an individual patient data meta-analysis from observational studies investigating the association between ADAMTS-13 levels and myocardial infarction.

Methods
A one-step meta-analytic approach with random treatment effects was used to estimate pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) adjusted for confounding. Analyses were based on dichotomous exposures, with the 5th and 1st percentiles of ADAMTS-13 antigen levels as cut-off values. Quartile analyses, with the highest quartile as a reference category, were used to assess a graded association between levels and risk (‘dose’ relationship). Additionally, we assessed the risk of the combined presence of low ADAMTS-13 and high von Willebrand factor (VWF) levels.

Results
Five studies were included, yielding individual data on 1501 cases and 2258 controls (mean age of 49 years). Low ADAMTS-13 levels were associated with myocardial infarction risk, with an OR of 1.89 (95% CI 1.15–3.12) for values below the 5th percentile versus above, and an OR of 4.21 (95% CI 1.73–10.21) for values below the 1st percentile versus above. Risk appeared to be restricted to these extreme levels, as there was no graded association between ADAMTS-13 levels and myocardial infarction risk over quartiles. Finally, there was only a minor synergistic effect for the combination of low ADAMTS-13 and high VWF levels.

Conclusions
Low ADAMTS-13 levels are associated with an increased risk of myocardial infarction.
Date Issued
2015-07-27
Date Acceptance
2015-05-20
Citation
Journal of Thrombosis and Haemostasis, 2015, 13 (8), pp.1396-1404
URI
http://hdl.handle.net/10044/1/26935
DOI
https://www.dx.doi.org/10.1111/jth.13032
ISSN
1538-7933
Publisher
Wiley
Start Page
1396
End Page
1404
Journal / Book Title
Journal of Thrombosis and Haemostasis
Volume
13
Issue
8
Copyright Statement
This is the peer reviewed version of the following article: Maino A, Siegerink B, Lotta LA, Crawley JTB, le Cessie S, Leebeek FWG, Lane DA, Lowe GDO, Peyvandi F, Rosendaal FR. Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis. J Thromb Haemost 2015; 13: 1396–404., which has been published in final form at https://dx.doi.org/10.1111/jth.13032.  This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Subjects
Science & Technology
Life Sciences & Biomedicine
Hematology
Peripheral Vascular Disease
Cardiovascular System & Cardiology
ADAMTS13 protein
human
blood coagulation
meta-analysis
myocardial infarction
risk factors
von Willebrand factor
VON-WILLEBRAND-FACTOR
THROMBOTIC THROMBOCYTOPENIC PURPURA
CLEAVING PROTEASE ADAMTS13
ISCHEMIC-STROKE
YOUNG-WOMEN
GENE
INCREASE
DISEASE
VWF
DEFICIENCY
Publication Status
Published
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback